Lipocine Inc(LPCN) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase 2b testing; LPCN 1148, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis cirrhosis (NASH); LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase 2 Clinical trial for the treatment of NASH. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Current Price

$1.36

RSI

27.766

Beta:

0.531163

March 11, 2021
5.6M
-3.7M

-37.014 %
-55.364 %

$0
$164,990
$428,031
$0
$0
$0
-Infinity %
-159.428 %
100.000 %
%
0.000 %

$-20,964,619
$-13,007,144
$-11,659,322
$-20,982,160
$-18,970,756
$-18,208,178
-37.957 %
-10.362 %
79.960 %
-9.586 %
-4.020 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.